Literature DB >> 18041069

Colorectal liver metastases contract centripetally with a response to chemotherapy: a histomorphologic study.

Jennica K S Ng1, Stefan J Urbanski, Naurang Mangat, Andrew McKay, Francis R Sutherland, Elijah Dixon, Scot Dowden, Scott Ernst, Oliver F Bathe.   

Abstract

BACKGROUND: Recently, there has been considerable interest in neoadjuvant chemotherapy for colorectal liver metastases. However, there is little information that defines how much liver should be removed after a favorable response.
METHODS: Liver metastases from 2 groups of patients were analyzed: 25 metastases were evaluated from a group that did not receive chemotherapy and 26 lesions were studied from patients who had received systemic chemotherapy before resection. All patients except for 1 had 5-fluorouracil (5-FU), leucovorin (LV), and irinotecan (CPT-11); 1 had 5-FU and LV alone. The average duration of chemotherapy was 2.9+/-0.7 months. Separate assessments of the histopathologic features of the central and peripheral portions of each tumor were made. The pathologist was blinded to all clinical information.
RESULTS: All of the untreated metastases had well-circumscribed borders. Irregular borders were seen in 6 of the postchemotherapy lesions (26%), which was particularly prominent in lesions that had significantly contracted. After chemotherapy, discrete islands of viable tumor cells outside of the main tumor mass were seen in 4 patients, but all were close to the peripheral margin of the tumor mass. Viable tumor cells were more frequent in the periphery of metastases, regardless of chemotherapy exposure. Central necrosis was prominent in untreated metastases, but disappeared after chemotherapy. In lesions treated with chemotherapy, central fibrosis was greater compared with untreated lesions.
CONCLUSIONS: After a partial response to chemotherapy, liver metastases shrank in a generally concentric fashion. These findings support the practice of removing less liver after downsizing with chemotherapy.

Entities:  

Mesh:

Year:  2008        PMID: 18041069     DOI: 10.1002/cncr.23184

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

Review 1.  Hepatic resection for colorectal metastases: the impact of surgical margin status on outcome.

Authors:  George A Poultsides; Richard D Schulick; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

2.  Assessment of the residual tumour of colorectal liver metastases after chemotherapy: diffusion-weighted MR magnetic resonance imaging in the peripheral and entire tumour.

Authors:  Mathilde Wagner; Maxime Ronot; Sabrina Doblas; Céline Giraudeau; Bernard Van Beers; Jacques Belghiti; Valérie Paradis; Valérie Vilgrain
Journal:  Eur Radiol       Date:  2015-05-02       Impact factor: 5.315

3.  Significance of R1 Resection for Advanced Colorectal Liver Metastases in the Era of Modern Effective Chemotherapy.

Authors:  Christophe Laurent; Jean-Philippe Adam; Quentin Denost; Denis Smith; Jean Saric; Laurence Chiche
Journal:  World J Surg       Date:  2016-05       Impact factor: 3.352

4.  Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy.

Authors:  Gabriel Chan; Mazen Hassanain; Prosanto Chaudhury; Dionisios Vrochides; Amy Neville; Matthew Cesari; Petr Kavan; Victoria Marcus; Peter Metrakos
Journal:  HPB (Oxford)       Date:  2010-05       Impact factor: 3.647

5.  Selection for hepatic resection of colorectal liver metastases: expert consensus statement.

Authors:  Reid B Adams; Thomas A Aloia; Evelyne Loyer; Timothy M Pawlik; Bachir Taouli; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2013-02       Impact factor: 3.647

Review 6.  Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens.

Authors:  Stéphanie Truant; Cédric Séquier; Emmanuelle Leteurtre; Emmanuel Boleslawski; Mehdi Elamrani; Guillemette Huet; Alain Duhamel; Mohamed Hebbar; François-René Pruvot
Journal:  HPB (Oxford)       Date:  2014-07-09       Impact factor: 3.647

7.  Liver resection for colorectal liver metastases with peri-operative chemotherapy: oncological results of R1 resections.

Authors:  Clarisse Eveno; Mehdi Karoui; Etienne Gayat; Alain Luciani; Marie-Luce Auriault; Michael D Kluger; Isabelle Baumgaertner; Laurence Baranes; Alexis Laurent; Claude Tayar; Daniel Azoulay; Daniel Cherqui
Journal:  HPB (Oxford)       Date:  2012-10-22       Impact factor: 3.647

8.  Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?

Authors:  Eran Sadot; Bas Groot Koerkamp; Julie N Leal; Jinru Shia; Mithat Gonen; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Nancy Kemeny; Leslie H Blumgart; William R Jarnagin; Michael I DʼAngelica
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

Review 9.  Missing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastases.

Authors:  Valerio Lucidi; Alain Hendlisz; Jean-Luc Van Laethem; Vincent Donckier
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

10.  A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.

Authors:  Oliver F Bathe; Scott Ernst; Francis R Sutherland; Elijah Dixon; Charles Butts; David Bigam; David Holland; Geoffrey A Porter; Jennifer Koppel; Scot Dowden
Journal:  BMC Cancer       Date:  2009-05-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.